Follow Us
   Twitter   YouTube

HFI News...

New Options for 1 out 3 Obese Americans  

The Food and Drug Administration (FDA) has approved two drugs addressing the major health problem of obesity. Belviq by Arena Pharmaceuticals and Osymia by Vivus Inc. provide hope for reducing weight and some of the serious health consequences of obesity. It is reported that the benefits of these drugs outweigh concerns of side effects including birth defects in newborns.

Belviq, taken twice a day, activates a receptor in the brain called serotonin 2 C, in a way that controls eating and makes people feel full.  The drug will not be available for 4 – 6 months and the cost has not yet been decided.

Osymia is an extended-release combination of two older drugs, phentermine and topiramate.  Phentermine is an amphetamine approved for
short-term weight loss. Topiramate is prescribed to prevent seizures as well as migraines, and it is supposed to make people feel fuller. It is advised that both drugs should be combined with exercise and a reduced-calorie diet to achieve maximum effectiveness.

For more information, contact:
Thelma K. Thiel